Brigham Young University (BYU) claimed that Monsanto Company (acquired by Pfizer in 2003) fraudulently breached an agreement to collaborate on the development of a non-steroidal, anti-inflammatory drug, or “super aspirin”, in the early 1990s. BYU claimed that Monsanto, its pharmaceutical subsidiary, G.D. Searle, and successor companies Pharmacia and Pfizer secretly misappropriated BYU’s work, concealed BYU’s role in the development of the anti-inflammatory drug Celebrex, and unjustly kept all the profits derived from its sale. Pfizer disclosed in a 2013 financial report that it settled the lawsuit for $450 million.